London Calling 2025 - Speakers
Speakers
Check out the line up of speakers at London Calling 2025.
A
Arianna CerutiLeipzig University, Germany
Ana Flavia PeresBarretos Cancer Hospital, Brazil
Adrien LegerDirector, Modified Base Research, Oxford Nanopore Technologies
Alberto MagiUniversity of Florence, Italy
Alimat OyawoyeNIHR BioResource, UK
Albert Perlas PuenteHelmholtz Munich, Germany
Alex TrotterDevelopment Scientist – Translational Development, Oxford Nanopore Technologies
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
Anna WierczeikoInstitute for Human Genetics, University Medical Center Mainz, Germany
B
Benjamin C. ReinerUniversity of Pennsylvania, USA
Basharat BhatSher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST), India
Bryant CatanoSenior Product Support Scientist, Oxford Nanopore Technologies
Brendan KeatingNYU Langone Health, USA
C
Chris AlderBioinformatician, Oxford Nanopore Technologies
Clive BrownChief Technology, Innovation, and Product Officer, Oxford Nanopore Technologies
Chloé BaumPasteur Institute, France
Dr. Charles K. CooperbioMérieux, France
Chloe GoldsmithTranslational Health Research Institute, Western Sydney University, Australia
Chris SeymourVP, Advanced Platform Development, Oxford Nanopore Technologies
Cora VacherAssociate Director, Market Segment, Oxford Nanopore Technologies
E
Eloisa ArbustiniIRCCS Foundation Policlinico San Matteo, Italy
Prof. Emma BapleUniversity of Exeter and South West NHS Genomics Laboratory Hub, UK
Eva Maria NovoaCentre for Genomic Regulation, Spain
H
Dr. Helen Bulbeckbrainstrust, UK
Hagan BayleyUniversity of Oxford, UK
Haoyu ChengYale University, USA
I
Ilaria CasconeUniversity of Naples Federico II, Italy
Ira DevesonGarvan Institute of Medical Research, Australia
Ivo GutNational Centre for Genomic Analysis, Spain
J
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
Javeria AijazIndus Hospital & Health Network, Pakistan
Judith BreuerUCL Institute of Child Health, UK
James BrayerDirector, Business Development, Nanopore Developers & Compatible Products Program, Oxford Nanopore Technologies
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
Joy GoffenaUniversity of Washington, USA
Jonathon HillWasatch BioLabs, USA
Jeff NivalaUniversity of Washington, USA
Jason WilliamsCold Spring Harbor Laboratory, USA
Jose-Crispin Zavala AlvaradoPathoQuest, France
K
Kieran O'NeillCanada's Michael Smith Genome Sciences Centre, Canada
Kathy StirrupsNIHR BioResource, UK
L
Lyn ChittyGreat Ormond Street NHS Foundation Trust & UCL Great Ormond Street Institute of Child Health, UK
Lucas Esteban WangePompeu Fabra University, Spain
Lakmal JayasingheChief Scientific Officer, Oxford Nanopore Technologies
Lennart KesterPrincess Máxima Center, The Netherlands
M
Mark AkesonUniversity of California, Santa Cruz, USA
Micah HoylmanUniversity of Nebraska Medical Center, USA
Mahreen KhanThe Hospital for Sick Children, Canada
Megan L. NoonanWashington University School of Medicine in St. Louis, USA
Mashiat Mimosa University of Toronto, Canada
Marcel NelenUMC Utrecht, The Netherlands
Michelle NgMichael Smith Laboratories, Canada
Matilda TierneyKing’s College London, UK
Michael WileyUniversity of Nebraska Medical Center, USA
N
Nadia DavidsonThe Walter and Eliza Hall Institute, Australia
Nathaniel EdisisBoston Children's Hospital, USA
Nathalie KingstonNIHR BioResource, UK
Nick OwensUniversity of Exeter, UK
P
Paul ArvidsonGenomics England & SWAN, UK
Pamela GanNalaGenetics, Singapore
Pauline Luise PfudererCRUK Cambridge Centre & Department of Pathology, University of Cambridge, UK
Patrick MurphyMarket Segment Manager for Single Cell, Oxford Nanopore Technologies
Prasad SarashettiA*STAR Genome Institute of Singapore, Singapore
Paula Saffie-AwadSanta Maria Clinic, Chile
R
Rafi AhmadUniversity of Inland Norway & University of Tromsø, Norway & University of Southampton, UK
Dr. Rahul BatraGuy's and St Thomas' NHS Foundation Trust UK
Ruben CoolsVIB-KU Leuven, Belgium
Rajesh PandeyCSIR-Institute of Genomics and Integrative Biology, India
Rute RegoInnovPlantProtect, Portugal
Rachel Samson P.Cranfield University, UK
Rhydian WindsorResearch Scientist, Machine Learning, Oxford Nanopore Technologies
S
Salvatore BenfattoDana-Farber Cancer Institute, USA
Sam DavisPrincipal Scientist, Machine Learning, Oxford Nanopore Technologies
Sarah FramptonUniversity of Southampton, UK
Sirisha HeskethClinical Bioinformatician, Oxford Nanopore Technologies
Skarphedinn HalldorssonOslo University Hospital, Norway
Steven HairNewcastle University, UK
Susie LeeTechnical Product Manager, Basecalling and Models, Oxford Nanopore Technologies
Sebastian LunkeVictorian Clinical Genetics Services, Australia
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
Sayonika MohantaStrategic Marketing Manager — Methylation, Oxford Nanopore Technologies
Steven RobbinsAustralian Centre for Ecogenomics, Australia
Spike WillcocksChief Strategy Officer, Oxford Nanopore Technologies
T
Thomas AlexanderUniversity of North Carolina, USA
Tomasz DobrzyckiField Applications Scientist, New Product Introduction, Oxford Nanopore Technologies
Tina HanTwist Bioscience
Thidathip WongsurawatMahidol University, Thailand
Oxford Nanopore Technologies
Dr. Thomas R. Kreil
- Job title
- Institution
- Takeda, Austria
- Biography
Beyond his work at Takeda, Dr. Thomas Kreil is Chairman of the Plasma Protein Therapeutics Association’s (PPTA) Pathogen Safety Steering Committee, a Steering Committee member of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), as coordinated by the Massachusetts Institute of Technology (MIT). He is also an Associate Professor at the Institute of Virology, Medical University of Vienna, Austria.
- Recent publications
Barone P.W. et al. Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS). Biologicals 81:101661 (2023). DOI:10.1016/j.biologicals.2022.11.003
Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in-vitro diagnostic devices in some jurisdictions, please check individual product labelling. Oxford Nanopore Technologies present the materials of third parties within the user community acknowledging that those materials belong to and are the true statements and representations of those third parties. Oxford Nanopore Technologies make no endorsements of the materials shown and the statements made.
